Table A2.
Overall survival in patients undergoing PCS.
| Characteristic | N | Hazard Ratio (95% CI) |
p | N | Hazard Ratio (95% CI) |
p |
|---|---|---|---|---|---|---|
| Age | ||||||
| <65 ≥65 |
76 52 |
Ref 2.57 (1.54–4.27) |
<0.001 |
50 42 |
Ref 2.88 (1.64–5.07) |
<0.001 |
| Stage | ||||||
| I/II | 25 | Ref | 14 | Ref | ||
| III/IV | 95 | 9.58 (2.33–39.37) | 0.002 | 73 | 6.44 (1.56–26.58) | 0.010 |
| Residual disease after PCS | ||||||
| Optimal | 103 | Ref | 74 | Ref | ||
| Suboptimal (>1 cm) | 9 | 4.16 (1.93–8.95) | <0.001 | 7 | 3.57 (1.47–8.65) | 0.005 |
| Any BRCA1 mutation | ||||||
| No | 69 | Ref | 44 | Ref | ||
| Yes | 21 | 0.56 (0.25–1.26) | 0.160 | 19 | 0.35 (0.15–0.85) | 0.020 |
| Any BRCA2 mutation | ||||||
| No | 108 | Ref | 74 | Ref | ||
| Yes | 10 | 0.15 (0.02–1.08) | 0.059 | 10 | 0.11 (0.01–0.79) | 0.029 |
| Any BRCA1/2 mutation | ||||||
| No | 62 | Ref | 37 | Ref | ||
| Yes | 31 | 0.36 (0.17–0.77) | 0.008 | 29 | 0.19 (0.08–0.44) | <0.001 |
| gNon-BRCA HR mutation | ||||||
| Negative | 80 | Ref | 53 | Ref | ||
| Positive | 5 | 1.97 (0.70–5.59) | 0.200 | 4 | 1.95 (0.68–5.58) | 0.214 |
| BRCA1 promoter methylation | ||||||
| <15 | 86 | Ref | 60 | Ref | ||
| ≥15 | 7 | 1.14 (0.41–3.17) | 0.804 | 6 | 0.68 (0.21–2.20) | 0.516 |
gNon-BRCA HR mutation = germline non-BRCA1/2 homologous recombination mutation. HGS = high-grade serous. HR = homologous recombination. HRD = homologous recombination deficiency. PCS = primary cytoreductive surgery.